Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice
Kenichi Serizawa, Shota Miyake, Yoshichika Katsura, Keigo Yorozu, Mitsue Kurasawa, Haruna Tomizawa-Shinohara, Hideyuki Yasuno, Yoshihiro Matsumoto
Abstract
We challenged to create a mouse model of neuromyelitis optica spectrum disorder (NMOSD) induced by AQP4 peptide immunization. Intradermal immunization with AQP4 p201-220 peptide induced paralysis in C57BL/6J mice, but not in AQP4 KO mice. AQP4 peptide-immunized mice showed pathological features similar to NMOSD. Administration of anti-IL-6 receptor antibody (MR16-1) inhibited the induction of clinical signs and prevented the loss of GFAP/AQP4 and deposition of complement factors in AQP4 peptide-immunized mice. This novel experimental model may contribute to further understanding the pathogenesis of NMOSD, elucidating the mechanism of action of therapeutic agents, and developing new therapeutic approaches.